Holston Medical Group’s Dr. David Morin appointed board chair of Association of Clinical Research Professionals (ACRP)
Published 12:14 pm Wednesday, January 26, 2022
KINGSPORT — Holston Medical Group (HMG) announced on Wednesday, Jan. 26, that Dr. David Morin, Director of Clinical Research at HMG, has been named the board chair of the Association of Clinical Research Professionals (ACRP), a non-proﬁt organization with more than 12,000 members that support clinical research in upwards of 70 countries. The board consists of 15 highly qualified Global leaders and accomplished individuals in the ﬁeld of Clinical Research and includes a public member. Through his new position, Dr. Morin continues to expand his leadership in the clinical trial space and internationally represent the local community and HMG in his efforts.
“It is an honor to be asked to serve in this capacity,” said Dr. Morin, who previously served as the Vice-Chair of the Board in 2021. “The team has their focus on the future of clinical research and workforce development. I look forward to working with the Executive Director, Fellow Trustees, the ACRP team, and our membership to continue to promote and advance excellence in clinical research.”
Before his appointment as board chair, Dr. Morin has served on multiple boards and committees aimed at improving the quality of research. Previous ACRP roles include serving as Treasurer, on the Certified Principal Investigator Committee, chair of the Awards and Recognition Committee, and liaison to the Academy Board. He is also currently on the Governance and Finance Committee. While serving in these positions, Dr. Morin has assisted in developing several training programs for both research coordinators and investigators which are still used by the Association. He continues to be involved in the training and educational aspects of the Association.
Over the last 35 years, Dr. Morin has been dedicated to supporting patients through the evolution of cutting-edge medicine. Most recently, as part of his role at HMG as director of clinical research efforts, director of the Eastman high-risk disease management program, and practicing healthcare provider, Dr. Morin’s team was selected by Prizer to conduct COVID-19 vaccine studies in Kingsport and Bristol. Through his and the larger community efforts in the trials, a national milestone in clinical research was set and millions have received scientifically backed protection against COVID-19. He now looks to continue these efforts by adapting processes both at HMG and at ACRP in light of the changing medical and research landscape.
“Dr. Morin has time and time again proven to be an incredible asset to Holston Medical Group as a liaison to the larger clinical research community. He is an innovator and is always helping to push the ﬁeld of medicine forward,” said Scott Fowler, MD, FACOG, president and CEO of HMG. “From his dedication to his patients’ health to the larger role he plays to ensure people like us in eastern Tennessee and southwest Virginia are represented appropriately in science, we’re proud to call him a member and leader at Holston Medical Group.”
For more information about Dr. Morin’s role in the ACRP, read his thoughts here: